Search
Harrow Inc
HROWAdd to Watchlist
41.500USD
-1.180-2.76%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
1.55BMarket Cap
LossP/E TTM
More Details of Harrow Inc Company
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Harrow Inc Info
Ticker SymbolHROW
Company nameHarrow Inc
IPO dateFeb 08, 2013
CEOMullery (Frank)
Number of employees382
Security typeOrdinary Share
Fiscal year-endFeb 08
Address1A Burton Hills Blvd
CityNASHVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code37215
Phone16157334731
Websitehttps://www.harrow.com/
Ticker SymbolHROW
IPO dateFeb 08, 2013
CEOMullery (Frank)
Company Executives of Harrow Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Randall E. Pollard, CPA
Mr. Randall E. Pollard, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Frank Mullery
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Chief Executive Officer of ImprimisRx
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
FAQs
Who are the top five shareholders of Harrow Inc?
The top five shareholders of Harrow Inc are: Mr. Mark L. Baum, J.D.
How many institutions hold shares of Harrow Inc (HROW)?
As of 2026Q1, 418 institutions hold shares of Harrow Inc, with a combined market value of approximately 24.67M, accounting for 66.17% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 347374.00.
